netFormulary NHS
Cambridgeshire and Peterborough
Formulary
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

THIS CHAPTER IS CURRENTLY UNDER REVIEW. FOR FURTHER ADVICE PLEASE CONTACT YOUR LEAD PHARMACIST OR CCG MEDICINES OPTIMISATION TEAM (PRIMARY CARE ENQUIRIES ONLY)

Formulary and commissioned oncology and haematology regimens

From April 2013 cancer treatments listed on the National Cancer Drug Fund list are funded through the NHS England as outlined on their dedicated website.

Treatments recommended in a NICE Technology Appraisal will be added to Formulary but may not always be provided at all centres (Some centres may not see the cohort of patients the NICE Technology Appraisal covers)

For patient information about chemotherapy and chemotherapy regimens, please see the Macmillan cancer support website: 

Royal Papworth Hospital NHS Foundation Trust does not routinely administer chemotherapy and does not have facilities for the preparation of injectable cytotoxic medication. If a patient requires treatment, usual practice is to transfer to an alternative hospital able to provide this service. The Trust accepts that an occasion may arise where transfer of the patient gives cause for concern. In this situation the Consultant wishing to prescribe cytotoxic medication must discuss the case directly with the Chief Pharmacist.

Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
Abemaciclib (Verzenios®)
(tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red Hospital
NHS England

  • Approved for use in line with

    • NICE TA563 - Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. 

    • NICE TA579 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. 



 
Link  NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
   
Afatinib (Giotrif®)
(Tablet)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red Hospital
NHS England

  • Approved in accordance with NICE TA310 for NSCLC.



  • Terminated appraisal NICE TA444 - Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy. 

 
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Link  NICE TA444 TERMINATED APPRAISAL: Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy
   
Cytotoxic Drug Aflibercept (Zaltrap®)
(Infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red Hospital
High Cost Medicine
Cancer Drugs Fund

  • Was approved accordance with the National Cancer Drugs Fund List for the second line treatment of metastatic colorectal cancer. Removed from the CDF list on 12th Match 2015. 



  • Remains on formulary for patients with funding approved prior to this date.

 
Link  NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
   
Alectinib (Alecensa®)
(Capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red Hospital

  • Approved for use in accordance with NICE TA536 for untreated ALK-positive advanced non-small-cell lung cancer. 

 
Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
   
Cytotoxic Drug Amsacrine (Amsidine®)
(Infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red Hospital
 
   
Cytotoxic Drug Arsenic Trioxide (Trisenox®)
(Infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red Hospital

  • Haematologist/oncologists ADULTS only. 



  • Approved in accordance with the Cancer Drug Fund as a fast-tracked drug for relapsed acute promyelocytic leukaemia (PML).



  • Approved for use in line with NICE TA526 for treating acute promyelocytic leukaemia. 

 
Link  MHRA Letters sent to healthcare professionals in May 2019: Trisenox (arsenic trioxide, 1 mg/ml concentrate for solution for infusion) - replacement with import of arsenic trioxide injection 1 mg/ml (Phenasen) into the UK during the supply shortage
Link  NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
   
Atezolizumab (Tecentriq®)
(Infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red Hospital
NHS England
BlueTeq

  • Approved for use in line with NICE TAs:


    • Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (NICE TA492).




    • Atezolizumab for treating locally advanced or metastatic non-small-cell lunch cancer after chemotherapy (NICE TA520). 




    • Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (NICE TA525).



    • Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (NICE TA584).



 
Link  NICE TA492: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
   
Avelumab (Bavencio®)
(Intravenous infusion )
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red Hospital
NHS England

 

  • Approved for use in accordance with NICE TA517 for treating metastatic Merkel cell carcinoma. 

 

  • CUHFT: Avelumab in combination with axitinib - Early Access to Medicines Scheme: First line treatment of adult patients with advanced renal cell carcinoma (RCC) (SSC2054. Agreed at September 2019 OSTS).
 
Link  NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
   
Axicabtagene ciloleucel (Yescarta®)
(intravenous infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red Hospital

  • Approved for use in accordance with NICE TA559 for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. 

 
Link  NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
   
Axitinib (Inlyta®)
(Tablet)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red Hospital
High Cost Medicine
  • Approved in accordance with NICE TA 333 for the treatment of advanced renal cell carcinoma after failure of a first-line kinase inhibitor or cytokine.

 

  • CUHFT: Axitinib in combination with avelumab - Early Access to Medicines Scheme: First line treatment of adult patients with advanced renal cell carcinoma (RCC) (SSC2054. Agreed at September 2019 OSTS).
 
Link  NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
   
Bexarotene (Targretin®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red Hospital
  • Clinically approved by JDTC, routinely commissioned.  
  • Link  MHRA Letters sent to healthcare professionals in June 2019: Retinoids▼ (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, and Tazarotene) - risk of teratogenicity and neuropsychiatric disorders
       
    Binimetinib (Mektovi®)
    (Tablets)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    NHS England

    • Approved for use in accordance with NICE TA562 - Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma. 
       

     
    Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
       
    Cytotoxic Drug Bortezomib (Velcade®)
    (Injection)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund

    • Approved for use in accordance with NICE:


      • TA129 for the treatment of progressive multiple myeloma in people who are at first relapse having received one prior therapy and who have undergone, or are unsuitable for, bone marrow transplantation.

      • TA228 for the first-line treatment of multiple myeloma if high-dose chemotherapy with stem cell transplantation is considered inappropriate and the person is unable to tolerate or has contraindications to thalidomide.

      • TA311 for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation.





    • TERMINATED APPRAISAL NICE TA453 for treating multiple myeloma after second or subsequent relapse.



    • Also approved in accordance with the National Cancer Drugs Fund List for the indication(s) below where the specified criteria are met:


      • The treatment of bortezomib naive relapsed multiple myeloma. Confirm CDF approval is in place before treatment by reference to Blueteq.





    • The following indications were removed from the CDF list on 12th March 2015. Treatment remains available for patients with funding approved prior to this date:


      • The treatment of relapsed/refractory mantle cell lymphoma.

      • The treatment of relapsed multiple myeloma that has previously responded to bortezomib.

      • The treatment of relapsed Waldenstrom's Macroglobulinaemia.

        For more information see Cancer Drug Fund List



     
    Link  MHRA - risk of cracked or broken vials - July 2014
    Link  NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
    Link  NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
    Link  NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
    Link  NICE TA453 TERMINATED APPRAISAL: Bortezomib for treating multiple myeloma after second or subsequent relapse
       
    Bosutinib (Bosulif®)
    (Tablets)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund

    • Apprived in accordance with NICE TA401 for use in chronic, accelerated and blast phase Philedelphia chromosome positive chronic myeloid leukaemia in adults if they have previously had one or more tyrosine kinase inhibitors, imatinib/nilotinib/dasatinib are not appropriate and it is discounted. 



    • Formerly approved in accordance with the National Cancer Drug Fund List the indications below where the specified criteria are met:


      • The treatment of chronic phase and accelerated phase Chronic Myeloid Leukaemia where other treatments are not tolerated. To be removed from the CDF on 4th November 2015. Remains on formulary for patients with funding approved prior to this date.

      • The treatment of blast crisis Chronic Myeloid Leukaemia where other treatments are not tolerated. To be removed from the CDF list on 12th March 2015. Remains on formulary for patients with funding approved prior to this date.





    • TERMINATED APPRAISAL NICE TA576 - Bosutinib for untreated chronic myeloid leukaemia. 

     
    Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
    Link  NICE TA576 TERMINATED APPRAISAL: Bosutinib for untreated chronic myeloid leukaemia
       
    Brentuximab vedotin (Adcetris®)
    (Infusion)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund
    BlueTeq

    • Only approved in accordance with the National Cancer Drugs Fund List for the indications below where the specified criteria are met:

      • The treatment of refractory systemic anaplastic lymphoma.

      • The treatment of relapsed or refractory CD30+ Hodgkin lymphoma.





    • Approved for use in line with NICE TA478 - Bretuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma.



    • Approved for use in line with NICE TA524 - Bretuximab vedotin for treating CD30-postiive Hodgkin lymphoma. 



    • Approved for use in line with NICE TA577 - Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma. 



    • Confirm funding approved on Bluteq for all new starters.
      For more information see Cancer Drug Fund List

     
    Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
    Link  NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
    Link  NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
       
    Brigatinib (Alunbrig®)
    (Tablets)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    NHS England

    • Restricted to use in line with NICE TA571 for treating ALK-positive advanced non-small-cell lung cancer after crizotinib. 

     
    Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
       
    Cytotoxic Drug Cabazitaxel (Jevtana®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund

    • Approved for use in line with NICE TA391.



    • Confirm funding approved on Bluteq for all new starters.


     
    Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
       
    Cabozantinib (Cabometyx®)
    (Tablets)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    NHS England

    • Approved in accordance with the National Cancer Drugs Fund List for the indication below where the specified criteria are met.



    • Approved for use in line with NICE TAs:

      • Carbozantinib for previously treated advanced renal cell carcinoma (NICE TA463).

      • Cabozantinib for untreated advanced renal cell carcinoma (NICE TA542).



     
    Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
    Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
       
    Cabozantinib (Cometriq®)
    (Capsule)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    Cancer Drugs Fund

    • Approved in accordance with the National Cancer Drugs Fund List for the indication below where the specified criteria are met:


      • The first line treatment of medullary thyroid cancer.





    • Approved for use in line with NICE TA516 - Cabozantinib for treating medullary thyroid cancer.



    • Confirm funding approved on Bluteq for all new starters. 




    • TERMINATED APPRAISAL NICE TA582 - Cabozantinib for previously treated advanced hepatocellular carcinoma. 

     
    Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
    Link  NICE TA582 TERMINATED APPRAISAL: Cabozantinib for previously treated advanced hepatocellular carcinoma
       
    Cytotoxic Drug Carboplatin
    (Injection)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
     
       
    Carfilzomib (Kyprolis®)
    (Infusion )
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    NHS England

    • In line with NICE TA457 for previously treated multiple myeloma. 

     
    Link  MHRA Drug Safety Update August 2019: Carfilzomib (Kyprolis▼) - reminder of risk of potentially fatal cardiac events
    Link  MHRA Drug Safety Update November 2019: Carfilzomib (Kyprolis▼) - risk of reactivation of hepatitis B virus
    Link  NICE TA457: Carfilzomib for previously treated multiple myeloma
       
    Cemiplimab (Libtayo®)
    (concentrate for solution for infusion)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund

    • Approved for use in line with NICE TA592 - Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma:

      • Cemiplimab is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults when curative surgery or curative radiotherapy is not appropriate. It is recommended only if the conditions in the managed access agreement are followed.



     
    Link  NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
       
    Ceritinib (Zykadia®)
    (Capsules)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    NHS England

    • Approved in accordances with NICE TAs:

      • Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (NICE TA395).

      • Ceritinib for untreated ALK-positive non-small-cell lung cancer (NICE TA500). 



     
    Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
    Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
       
    Cetuximab (Erbitux®)
    (Infusion)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund

    Approved in accordance with NICE:



    • TA145 for the treatment of locally advanced squamous cell cancer of the head and neck where platinum-based treatment is contraindicated. 



    • TA176 for the first-line treatment of metastatic colorectal cancer where the metastatic disease is confined to the liver but is unresectable and the patient is fit enough to undergo surgery to resect the primary tumour and the liver if the metastases become resectable.



    • TA473 for treating recurrent or metastatic squamous cell cancer of the head and neck.


    Also approved in accordance with the National Cancer Drugs Fund List for the indication(s) below where the specified criteria are met:



    • The first line treatment of advanced head and neck cancer.



    • The first line treatment of metastatic colorectal cancer that does not meet the criteria of NICE TA176.



    • The second or third line treatment of metastatic colorectal cancer with combination chemotherapy. Was removed from the CDF list on 12th March 2015. Remains on formulary for patients with funding approved prior to this date.



    • The third or fourth line treatment of metastatic colorectal cancer as a single agent. 

      For more information see Cancer Drug Fund List.

     
    Link  MHRA Drug Safety Update February 2014: Cetuximab - importance of establishing wild type RAS (KRAS and NRAS) status before treatment of metastatic colorectal cancer
    Link  NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
    Link  NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer
    Link  NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
       
    Cytotoxic Drug Cisplatin
    (Injection)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
     
       
    Crizotinib (Xalkori®)
    (Capsule)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    • Only approved in accordance with the National Cancer Drugs Fund List for the indications below where the specified criteria are met:


      • Approved in accordance with NICE TA406 - Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.

      • Approved in accordance with NICE TA529 - Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer. 




     
    Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.
    Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
       
    Dabrafenib (Tafinlar®)
    (Capsule)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund

    • Approved in line with NICE TA321 for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma.



    • Approved in line with NICE TA396 for treating unresectable or metastatic melanoma in combination with trametinib.



    • Approved in line ith NICE TA544 for adjuvant treatment of resected BRAF V600 mutation-positive melanoma with trametinib. 



    • TERMINATED APPRAISAL NICE TA564 Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer.


     
    Link  NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
    Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
    Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
    Link  NICE TA564 TERMINATED APPRAISAL: Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer
       
    Cytotoxic Drug Dacarbazine
    (Injection)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
     
       
    Dacomitinib  (Vizimpro® )
    (Tablets)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    • Approved for use in line with NICE TA595 - Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer. 
     
    Link  NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
       
    Daratumumab (Darzalex®)
    (Infusion)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    NHS England

    • TERMINATED APPRAISAL NICE TA454 - Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma.



    • For use in line with NICE TA510 - Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. 



    • For use in line with NICE TA573 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. 

     
    Link  MHRA Drug Safety Update August 2019: Daratumumab (Darzalex▼)- risk of reactivation of hepatitis B virus
    Link  MHRA Letters sent to healthcare professionals in June 2019: Darzalex▼(daratumumab) and risk of reactivation of hepatitis B virus
    Link  NICE TA454 TERMINATED APPRAISAL: Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
    Link  NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
    Link  NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
       
    Dasatinib (Sprycel®)
    (Tablet)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund
    • Approved in accordance with the National Cancer Drugs Fund List for the indication(s) below where the specified criteria are met:
      • The treatment of Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia.
      • The treatment of chronic phase chronic myeloid leukaemia.
      • The treatment of accelerated phase chronic myeloid leukaemia.
      • The treatment of lymphoid blast crisis chronic myeloid leukaemia. Was removed from the CDF list on 12th March 2015. Remains on formulary for patients with funding approved prior to this date.
    • Approved for use in line with NICE TA426Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia. 
    • Confirm funding approved on BlueTeq for all new starters.
     
    Link  NICE TA251: Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia
    Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
       
    Cytotoxic Drug Docetaxel (Taxotere®)
    (Infusion)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
  • As per NICE TA 101 and 109.
    1) Oncologists as approved by NICE for non small cell lung cancer.
    2) Oncologists with tratuzumab for HER2-expressing breast cancers.
    3) Oncologists for Ovarian cancer.  
  • Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
    Link  NICE TA109: Breast cancer (early) - docetaxel
       
    Encorafenib (Braftovi®)
    (Capsules)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    NHS England

    • Approved for use in accordance with NICE TA562 - Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma. 
       

     
    Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
       
    Cytotoxic Drug Eribulin (Halaven®)
    (Injection)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund

     



    • In line with NICE TA423 - Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens. 



    • NOT RECOMMENDED in line with NICE TA515 - Eribulin for treating locally advanced or metastatic breast cancer agter 1 chemotherapy regimen. CUHFT Compliant. 



    • Approved in accordance with the National Cancer Drugs Fund List for the indications below where the specified criteria are met:


     
    Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
    Link  NICE TA515 NOT RECOMMENDED NEGATIVE: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
       
    Erlotinib (Tarceva®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
  • Approved in accordance with NICE TA162 and TA258.
  • Not to be used as monotherapy.  
  •    
    Erlotinib (Tarceva® )
    (Tablets)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
  • Approved in accordance with NICE TA162 and TA258.
  • Red HOSPITAL only.
  • Expected usage low. 
  • Link  NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib
    Link  NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
       
    Everolimus (Afinitor®)
    (Tablet)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund

    Only approved in accordance with the National Cancer Drugs Fund List for the indication(s) below where the specified criteria are met in line with NICE TAs:



    • Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (NICE TA421)

    • The treatment of well differentiated pancreatic neuroendocrine carcinomas.

    • Everolimus for advanced renal cell carcinoma after previous treatment (NICE TA432)

    • Everolimus and Sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (NICE TA449). 


    Removed from the CDF list on 12th March 2015:



    • The treatment of moderately differentiated pancreatic neuroendocrine carcinomas.


    Removed from the CDF list on 21st July 2015. Remains on the formulary for patients with funding previously.


    The treatment of metastatic renal cell carcinoma in patients treated with only one previous tyrosine kinase inhibitor and with a contraindication to 2nd line axitinib therapy or excessive toxicity with axitinib necessitating discontinuation within 3 months of starting therapy.



    • Confirm funding approved on BlueTeq for all new starters.

      For more information see Cancer Drug Fund List

     
    Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy.
    Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
    Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
       
    Everolimus (Votubia®)
    (Tablet, Dispersible tablets )
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    NHS England
    BlueTeq
    • This is not recommended for preventing organ rejection in liver transplantation.
    • Approved for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in paediatrics in line with NHSE CCP 16066/P.
    • Dispensed via Outpatient Pharmacy.
    • CAUTION WITH BRAND PRESCRIBED - Afinitor® is on formulary as per restrictions. 
    • Approved for use in line with NHSE CCP B14X09 for treatment of angiomyolipomas associated with tuberous sclerosis for angiomyolipomas (AMLs) which are 30 mm or greater and which demonstrate interval growth.
    • Approved for use in line with NHSE CCP 170093P - Everolimus  for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above - paediatrics only).

     

     
    Link  NHSE Clinical Commissioning Policy 16066/PP: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (paediatrics only)
    Link  NHSE Clinical Commissioning Policy 170093P: Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above), paediatrics only
    Link  NHSE Clinical Commissioning Policy Statement B14X09: Everolimus (Votubia®) for treatment of angiomyolipomas associated with tuberous sclerosis
       
    Gefitinib (Iressa®)
    (Tablet)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
  • Approved in accordance with NICE TA192 for NSCLC
     
  • Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
       
    Gemtuzumab ozogamicini (Mylotarg®)
    (Infusion)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital

    • Approved for use in accordance with NICE TA545 for untreated acute myeloid leukaemia. 

     
    Link  NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
       
    Cytotoxic Drug Hydroxycarbamide
    (Capsule)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Amber SCG

    • CUHFTonly: Shared Care Agreement for the for the treatment of myeloproliferative neoplasms (polycythaemia vera, essential thrombocythaemia and primary myelofibrosis) (Adults)

    • All other indications are Hospital Only

    • Unlicensed suspension is available for paediatrics not able to swallow tablets/capsules.

     
    Link  CUHFT: Shared Care Guideline - Hydroxycarbamidefor the treatment of myeloproliferative neoplasms treatment in adults
       
    Ibrutinib (Imbruvica®)
    (Capsules)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    NHS England

     

    • TERMINATED APPRAISAL NICE TA452 for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation. 
    • In line with NICE TA491 for treating Waldenstrom’s macroglobulinaemia.
    • In line with NICE TA502 for treating relapsed or refractory mantle cell lymphoma. 

     

     
    Link  NICE TA452 TERMINATED APPRAISAL: Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation
    Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
    Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
       
    Cytotoxic Drug Idelalisib (Zydelig®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    Cancer Drugs Fund

     

    • As per NICE TA359.
    • Approved at OSTS June 2016, funding not in place.
    • Commissioning approval for activity needs completion.
    • TERMINATED APPRAISAL NICE TA469 - Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia. 
    • NOT RECOMMENDED NICE TA604 - Idelalisib for treating refractory follicular lymphoma. 

     

     
    Link  NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
    Link  NICE TA469 TERMINATED APPRAISAL: Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia
    Link  NOT RECOMMENDED NICE TA604: Idelalisib for treating refractory follicular lymphoma
       
    Cytotoxic Drug Imatinib (Generic)
    (Tablets)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    Generic imatinib (Wockhardt formulation) is not licensed for gastrointestinal stromal tumours (GIST).

    Approved in accordance with NICE:
  • NICE TA70 For chronic myeloid leukaemia.
  • NICE TA326 Imatinib for the adjuvant treatment of gastro0intestinal stromal tumours.
  • NICE TA86 Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours.
  • NICE TA251 Dasatinib, nilotinib and stardard-dose imatinib for the first-line treatment of chronic myeloid leukaemia.  
  •    
    Cytotoxic Drug Imatinib (Gilvec®)
    (Tablet)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Approved in accordance with NICE:
  • NICE TA70 For chronic myeloid leukaemia.
  • NICE TA326 Imatinib for the adjuvant treatment of gastro0intestinal stromal tumours.
  • NICE TA86 Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours.
  • NICE TA251 Dasatinib, nilotinib and stardard-dose imatinib for the first-line treatment of chronic myeloid leukaemia.

    Also approved in accordance with the National Cancer Drugs Fund List for the indication(s) below where the specified criteria are met:
  • The adjuvant treatment of gastrointestinal stromal tumour patients with exon 11 mutation

  •  
       
    Inotuzumab ozogamicin (Besponsa®)
    (Intravenously)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital

    • Approved for use in accordance with NICE TA541 for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. 

     
    Link  NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
       
    Ipilimumab (Yervoy®)
    (Intravenous infusion)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    Cancer Drugs Fund
    • Approved in accordance with NICE TA268 - for previously treated advanced (unresectable or metastatic) melanoma
    • Approved in accordance with NICE TA319 - for previously untreated advanced (unresectable or metastatic) melanoma (NHS England has confirmed that funding will be in place from 21st October 2014)
    • Approved in line with NICE TA400 for treating advanced (unresectable or metastatic) melanoma in adults in combination with nivolumab.
      For more information see Cancer Drug Fund List
    • CUH: interim approval of limited FOC scheme Nivolumab and Ipilumab combination for MMR colorectal cancer - JDTC Nov 2019
     
    Link  MHRA Drug Safety Update: Ipilimumab (Yervoy) - reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
    Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
    Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
    Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced
       
    Cytotoxic Drug Irinotecan Hydrochloride
    (Infusion)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
  • Oncologists - Relapsed Metastatic Colorectal Cancer after 5-Fluorouracil in patients of good performance status (0-1).
  • Maximum 10 patients a year.  
  •    
    Ixazomib (Ninlaro®)
    (Capsules)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    NHS England
    BlueTeq

    • Approved for use in accordance with NICE TA505 - Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. 

     
    Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
       
    Lapatinib (Tyverb®)
    (Tablet)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
  • Approved in accordance with the National Cancer Drugs Fund List for the indication(s) below where the specified criteria are met:
  • The treatment of advanced breast cancer. To be removed from the CDF list on 12th March 2015. Remains on formulary for patients with funding approved prior to this date.

  • Confirm funding approved on BlueTeq for all new starters. 
  • Link  MHRA Letters sent to healthcare professionals in May 2019: Lapatinib (Tyverb) - important update to the therapeutic indication and Summary of Product Characteristics
    Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
       
    Lenvatinib (Kisplyx®)
    (Capsules)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    NHS England

    • Approved for use in accordance with NICE TA498 - Lenvatinib with everolimus for previously treated advanced renal cell carcinoma. 

     
    Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
       
    Lenvatinib (Lenvima®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    NHS England

    • Approved for use in accordance with NICE TAs: 

      • Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (NICE TA535).

      • Lenvatinib for untreated advanced hepatocellular carcinoma (NICE TA551).





    • CUHFT: Hospital only via Lloyds OP.

     
    Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
    Link  NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
       
    Liposomal Cytarabine–Daunorubicin  (Vyxeos®)
    (Intravenous infusion )
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    NHS England

    • Approved for use in accordance with NICE TA552 - Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia. 



    • CUHFT: Hospital only via Cytos pharmacy.

     
    Link  NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
       
    Midostaurin (Rydapt® )
    (Capsules )
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    NHS England

    • Approved for use in line with NICE TA523 for untreated acute myeloid leukaemia. 

     
    Link  NICE TA523: Midostaurin for untreated acute myeloid leukaemia
       
    Mitotane (Lysodren®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
     
       
    Nilotinib (Tasigna®)
    (Capsule)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
  • Restricted to imatinib refractory or intolerant patients in treatment of CML.
    li>See EastMidlands Cancer network guidelines linked above for further information with regards to Nilotinib place in CML therapy.
  • Approved as per NICE TA251 and TA241. 
  • Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
    Link  NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
       
    Niraparib (Zejula®)
    (Capsules)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    NHS England

    • Approved for use in accordance with NICE TA528 for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer. 

     
    Link  NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
       
    Cytotoxic Drug Olaparib (Lynparza®)
    (Capsule)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    Cancer Drugs Fund

     

    • Approved as per NICE TA381 for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy.
    • Approved as per NICE TA598 for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy. 
    • Olaparib access programme (FOC) – Maintenance treatment of BRCA-mutated ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy.

     

     
    Link  NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
    Link  NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
       
    Cytotoxic Drug Osimertinib (Tagrisso®)
    (Tablets)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
  • As per NICE TA416.
  • Also approved in accordance with the National Cancer Drugs Fund List.
    For more information see Cancer Drug Fund List
     
  • Link  NICE TA416: 6. Osimertinib for treating locally advanced or metastatic EGFR T790 mutation-positive nonsmall-cell lung cancer
       
    Cytotoxic Drug Oxaliplatin
    (Injection)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
  • As per NICE TA100 in the adjuvant treatment of stage 3 (Dukes' C) colon cancer.
  • 2nd line treatment in metastasising colorectal cancer when therapy with 5FU alone has failed.  
  • Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
       
    Cytotoxic Drug Paclitaxel
    (Infusion)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    NHS England

    •Approved for use in line with NICE TA389
    •Overall chemo spend to be tracked against income in-year until further notice.

     
    Link  NICE TA389: Recurrent ovarian cancer
       
    Cytotoxic Drug Paclitaxel - Albumin Bound Formulation (Abraxane®)
    (Intravenous infusion)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
  • Approved for the treatment of breast cancer in patients who have documented Taxane hypersensitivity, in accordance with routine NHSE commissioning.
  • Also approved in accordance with the National Cancer Drugs Fund List for the indication(s) below where the specified criteria are met:
  • The first line treatment of advanced adenocarcinoma of the pancreas in combination with gemcitabine.
  • Confirm funding approved on BlueTeq for all new starters
    For more information see Cancer Drug Fund List 
  • Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
       
    Palbociclib (Ibrance®)
    (Capsules)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    Cancer Drugs Fund
    NHS England

     

    • Approved for use in line with NICE TA495 - Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. 
    • Approved for use in line with NICE TA619 - Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer. 

     

     
    Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
    Link  NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
       
    Pazopanib (Votrient®)
    (Tablets)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
  • Approved in accordance with NICE TA215 for the first-line treatment of advanced renal cell carcinoma
  • Also approved in accordance with the National Cancer Drugs Fund List for the indications below where the specified criteria are met:
  • The treatment of advanced non-adipocytic soft tissue sarcoma. To be removed from the CDF list on 12th March 2015. Remains on formulary for patients with funding approved prior to this date.
  • Confirm funding approved on BlueTeq for all new starters.
    For more information see Cancer Drug Fund List
     
  • Link  NICE TA 215: Pazopanib in renal cell cancer
       
    Pembrolizumab (Keytruda®)
    (Injection)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq
    • Approved in accordance with:
      • NICE TA357 for advanced melanoma after disease progression with ipilimumab.
      • NICE TA366 for advanced melanoma not previously treated with ipilimumab.
      • NICE TA428 for treating PD-L1-positive non-small-cell lung cancer after chemotherapy. 
      • NICE TA519 for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. 
      • NICE TA522 for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable. 
      • NICE TA531 for untreated PD-L1-positive metastatic non-small-cell lung cancer.
      • NICE TA553 for adjuvant treatment of resected melanoma with high risk of recurrence. 
      • NICE TA557 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer.
      • NICE TA600 - Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer.
    • NICE TA540 NOT RECOMMENDED for treating relapsed or refractory classical Hodgkin lymphoma. 
    • TERMINATED APPRAISAL NICE TA570 for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy.
    • Approved in accordance with:Early Access to Medicines Scheme for the treatment of non-small cell lung cancer.
     
    Link  NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
    Link  NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
    Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
    Link  NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
    Link  NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
    Link  NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
    Link  NICE TA540 NOT RECOMMENDED: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
    Link  NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
    Link  NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
    Link  NICE TA570 TERMINATED APPRAISAL: Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy
    Link  NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
       
    Cytotoxic Drug Pentostatin (Nipent®)
    (Injection)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
     
       
    Cytotoxic Drug Pertuzumab (Perjeta®)
    (Infusion)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund

    • Only Approved in accordance with the National Cancer Drugs Fund List for the first line treatment of locally advanced or metastatic breast cancer.



    • Approved in accordance with NICE TAs:

      • NICE TA424 - Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer.

      • NICE TA509 - Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer.

      • NICE TA569 - Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer. 



    • For more information see Cancer Drug Fund List

     
    Link  NICE TA424 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
    Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
    Link  NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
       
    Ponatinib (Iclusig®)
    (Tablet)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund


    • Approved for use in line with NICE TA451 - for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia.

     
    Link  MHRA Drug Safety Update December 2014: Ponatinib - risk of vascular occlusive events
    Link  MHRA Drug Safety Update October 2018: Ponatinib - reports of posterior reversible encephalopathy syndrome
    Link  NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
       
    Cytotoxic Drug Procarbazine
    (Capsule)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
     
       
    Regorafenib (Stivarga® )
    (Tablets)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund

    • Approved in line with NICE TA555 (replaced NICE TA514) - Regorafenib for previously treated advanced hepatocellular carcinoma.



    • Approved in line with NICE TA488 for previously treated unresectable or metastatic gastrointestinal stromal tumours. 



    • Approved in accordance with the National Cancer Drugs Fund List for the treatment of adult patients with advanced gastro-intestinal stromal tumours (GIST) after failure of at least previous imatinib and sunitinib.



    • Confirm funding approved on BlueTeq for all new CDF starters
      For more information see Cancer Drug Fund List

     
    Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
    Link  NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
       
    Ribociclib (Kisqali®)
    (Tablets)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    Cancer Drugs Fund
    NHS England
    BlueTeq

     

    • Approved for use in line with NICE TAs:
      • NICE TA496 - Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. 
      • NICE TA593 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer.
    • CUHFT: Hospital only via Lloyds OP.

     

     
    Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
    Link  NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
       
    Rucaparib (Rubraca®)
    (Tablets)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    Cancer Drugs Fund
    • Approved for use in line with NICE TA611 for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. 
     
    Link  NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
       
    Ruxolitinib (Jakavi®)
    (Tablet)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund
  • Approved from 7th June 2016 in accordance with NICE TA386 for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in people with intermediate-2 or high risk disease only.
  • Use in people with intermediate-1 disease was removed from the Cancer Drugs Fund on 7th June 2016 and will no longer be available from that date. People with intermediate-1 disease already receiving ruxolitinib via the CDF have the option to continue treatment until they and their clinician consider it appropriate to stop.

  • Confirm funding approved vis the Cancer Drug Fund for all new starters
    For more information see Cancer Drug Fund List 
  • Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
       
    Sorafenib (Nexavar®)
    (Tablets)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund

    • Approved in accordance with NICE TA474 for treating advanced hepatocellular carcinoma. 



    • Approved in accordance with NICE TA535 - Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine. 



    • Approved in accordance with the National Cancer Drugs Fund List for the indication(s) below where the specified criteria are met:


      • The first line treatment of advanced hepatocellular carcinoma.

      • The treatment of papillary or follicular thyroid cancer.





    • Confirm funding approved via the Cancer Drug Fund for all new starters.
      For more information see Cancer Drug Fund List.

     
    Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
    Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
       
    Streptozocin (Zanosar®)
    (powder for concentrate for solution for infusion )
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    NHS England

    • NWAFT only - funded by NHSE for neuroendocrine tumours of pancreatic origin.  

     
       
    Sunitinib (Sutent®)
    (Capsules)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund

    • Approved in accordance with NICE TAs:

      • NICE TA179 for the treatment of gastrointestinal stromal tumours

      • NICE TA169 for the first-line treatment of advanced and/or metastatic renal cell carcinoma.

      • NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease



    • Also approved in accordance with the National Cancer Drugs Fund List for the treatment of pancreatic neuroendocrine carcinomas.

    • Confirm funding approved on BlueTeq for all new starters.

      For more information see Cancer Drug Fund List

     
    Link  NICE TA169: Sunitinib for advanced or metastatic renal cell carcinoma
    Link  NICE TA179: Sunitinib for the treatment of gastro-intestinal stromal tumours
    Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
       
    Talimogene laherparepvec (Imlygic®)
    (Injection)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
  • Approved in accordance with NICE TA410 Talimogene laherparepvec for treating unresectable metastatic melanoma.
  • BlueTeq required.
     
  • Link  NICE TA410 Talimogene laherparepvec for treating unresectable metastatic melanoma
       
    Cytotoxic Drug Temozolomide (Temodal®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
  • Licensed for use in glioblastoma. For use in CNS lymphoma please refer to protocol linked below.
  • Approved as per NICE TA23 Temozolomide for the treatment of recurrent malignant glioma (brain cancer).
     
  • Link  MHRA: risk of hepatic injury, including fatal hepatic failure
    Link  NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
    Link  NICE TA23: Temozolomide for the treatment of recurrent malignant glioma (brain cancer)
       
    Cytotoxic Drug Temsirolimus (Torisel®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund
  • Approved in accordance with the National Cancer Drugs Fund List for the treatment of advanced renal cell carcinoma


  • Confirm funding approved on BlueTeq for all new CDF starters.
    For more information see Cancer Drug Fund List 
  • Link  Drugs and Therapeutics Website
       
    Tisagenlecleucel  (Kymriah®)
    (Infusion )
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    Cancer Drugs Fund
    NHS England

    • Approved for use in accordance with NICE TAs:

      • NICE TA554 for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. 

      • NICE TA567 for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. 



     
    Link  NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
    Link  NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
       
    Tivozanib (Fotivda®)
    (Capsules)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital

    • Approved for use in line with NICE TA512 - Tivozanib for treating advanced renal cell carcinoma.

     
    Link  NICE TA 512: Tivozanib for treating advanced renal cell carcinoma
       
    Cytotoxic Drug Topotecan (Hycamtin®)
    (Infusion, Capsule)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
  • Approved in accordance with NICE TA184 and NICE TA389.
  • Overall chemo spend to be tracked against income in-year until further notice. 
  • Link  NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
    Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
       
    Cytotoxic Drug Trabectedin (Yondelis®)
    (Injection)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    •Approved for use in line with NICE TA185 for soft tissue sarcoma.
    •Overall chemo spend to be tracked against income in-year until further notice
     
    Link  NICE TA185: Trabectedin for the treatment of advanced soft tissue sarcoma
       
    Trametinib (Mekinist®)
    (Tablets)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital

    • For use in accordance with NICE TAs:


      • Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (NICE TA396).




      • Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (NICE TA544).





    • TERMINATED APPRAISAL NICE TA564 Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer. 

     
    Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
    Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
    Link  NICE TA564 TERMINATED APPRAISAL: Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer
       
    Cytotoxic Drug Trastuzumab (Herceptin®)
    (Infusion)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital

    • Approved in line with NICE guidance and in accordance with the Cancer Drugs Fund.

    • Oncologists - for HER2 breast cancer with docetaxel.

      **Care required**
      To minimise the risk of errors due to the similarity of the product name:
      -Kadcyla® (trastuzumab emtansine) 
      -Herceptin® IV (trastuzumab)
      -Herceptin® SC (trastuzumab)

    • The recommendations in the Risk Minimisation Plan educational material from the manufacturer, should be followed when prescribing, dispensing and administering the product.

     
    Link  NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
    Link  NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
    Link  NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
       
    Cytotoxic Drug Trastuzumab emtansine (Kadcyla®)
    (Infusion)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    NHS England

    • For use in accordance with NICE TA458 - Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane. 


    **Care required** 
    To minimise the risk of errors due to the similarity of the product name: 
    -Kadcyla® (trastuzumab emtansine) 
    -Herceptin® IV (trastuzumab)
    -Herceptin® SC (trastuzumab)



    • The recommendations in the Risk Minimisation Plan educational material from the manufacturer, should be followed when prescribing, dispensing and administering the product.

     
    Link  NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
       
    Tretinoin (Vesanoid®)
    (Capsule)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
  • For the treatment of Acute Pro-myelocytic Leukaemia.
  • Also known as 'All Trans Retinoic Acid' (ATRA).  
  • Link  MHRA Letters sent to healthcare professionals in June 2019: Retinoids▼ (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, and Tazarotene) - risk of teratogenicity and neuropsychiatric disorders
       
    Vemurafenib (Zelboraf®)
    (Tablet)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
  • As per NICE TA269 Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.
     
  • Link  NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
       
    Venetoclax (Venclyxto®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund

    • Approved in line with NICE TAs:

      • NICE TA487 for treating chronic lymphocytic leukaemia.

      • NICE TA561 with rituximab for previously treated chronic lymphocytic leukaemia. 



     
    Link  NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
    Link  NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
       
    Cytotoxic Drug Vismodegib (Erivedge®)
    (Capsule)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red Hospital
    High Cost Medicine
    Cancer Drugs Fund

    • Only approved in accordance with the National Cancer Drugs Fund List for the treatment of locally advanced or metastatic Basal Cell Carcinoma.

    • Note: Patient, prescriber, and supplying pharmacy must comply with the manufacturer’s pregnancy prevention programme.
      For more information see Cancer Drug Fund List.

    • TERMINATED APPRAISAL NICE TA489 for treating basal cell carcinoma. 


     

     
    Link  NICE TA489 TERMINATED APPRAISAL: Vismodegib for treating basal cell carcinoma
       
     ....
     Non Formulary Items
    Carboplatin  (Paraplatin®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Grey
     
    Crisantaspase  (Erwinase®)
    (Injection)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Grey


    Link  Letter: ERWINASE® Batch 160G Variation Information (July 2013)
     
    Ibrutinib  (Imbruvica®)
    (Tablets)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Grey
     
    Necitumumab

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Grey
    High Cost Medicine
     
    Olaratumab  (Lartruvo®)
    (Infusion)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black

    • No new patients to be started following the MHRA alert June 2019. Alternative treatment to be considered for patients started on treatment in line with NICE TA465 - Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma.

    Link  MHRA Drug Safety Update June 2019: Lartruvo▼ (olaratumab) - withdrawal of the EU marketing authorisation due to lack of efficacy
    Link  MHRA Letters sent to healthcare professionals in May 2019: Lartruvo▼ (olaratumab) - withdrawal of the EU marketing authorisation due to lack of therapeutic efficacy
    Link  MHRA Letters sent to healthcare professionals in May 2019: Lartruvo▼ (olaratumab) - withdrawal of the EU marketing authorisation due to lack of therapeutic efficacy
    Link  NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
     
    Oxaliplatin  (Eloxatin®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Grey
     
    Paclitaxel  (Taxol®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Grey
     
    Padeliporfin  (Tookad®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black

    • NOT RECOMMENEDED IN LINE WITH NICE TA546 for untreated localised prostate cancer.



    • Padeliporfin is not recommended, within its marketing authorisation, for untreated, unilateral, low-risk prostate cancer in adults. 

    Link  NICE TA546: Padeliporfin for untreated localised prostate cancer (Not Recommended)
     
    Cytotoxic Drug  Panitumumab  (Vectibix®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Grey
    High Cost Medicine
    Cancer Drugs Fund

    • Approved in accordance with the National Cancer Drugs Fund List for the indications below where the specified criteria are met:

      The first line treatment of metastatic colorectal cancer.

      The third or fourth line treatment of metastatic colorectal cancer as a single agent. To be removed from the CDF list on 4th November 2015. Remains on formulary for patients with funding approved prior to this date.

      For more information see Cancer Drug Fund List

     
    Cytotoxic Drug  Pegylated liposomal Irinotecan  (Onivyde®)
    (Infusion)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black

    • Not recommended NEGATIVE in line with NICE TA440 - Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine

    Link  MHRA Drug Safety Update March 2019: Onivyde (irinotecan, liposomal formulations) - reports of serious and fatal thromboembolic events
    Link  NICE TA440 NOT RECOMMENDED NEGATIVE: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
     
    Porfimer Sodium  (Photofrin ®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Grey
     
    Ramucirumab  (Cyramza®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Grey
    High Cost Medicine
    Link  NICE TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
     
    Sonidegib  (Odomzo®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Grey

    No formal assessment

     
    Temoporfin  (Foscan®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Grey
     
    Cytotoxic Drug  Trastuzumab  (Trazimera®)
    (Infusion)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Grey
     
    Cytotoxic Drug  Vandetanib  (Caprelsa®)
    (Tablets)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    High Cost Medicine
    Cancer Drugs Fund

    • NOT RECOMMENDED NEGATIVE in line with NICE TA550 for treating medullary thyroid cancer. 

    Link  NICE TA550 NOT RECOMMENDED NEGATIVE: Vandetanib for treating medullary thyroid cancer
     
    Vosaroxin  (Qinprezo)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Grey
    High Cost Medicine
     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to children's BNF
    click to search medicines.org.uk
    Link to SPCs
    SMC
    Scottish Medicines Consortium
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    OTC

    Available Over the Counter. Consider Self Care   

    Green

    Formulary - Can be prescribed in both secondary and primary care.   

    Advice

    Formulary - Specialist Advice, secondary care advice provided for primary care initiation.  

    Amber No SCG

    Formulary - Specialist initiation without shared care guidance.  

    Amber SCG

    Formulary - Specialist initiation with shared care guidance.  

    Red Hospital

    Restricted - Hospital only, not to be prescribed in primary care.  

    Switch

    Not recommended for prescribing. Switch to alternative cost-effective option.   

    Black

    Not recommended for prescribing in primary or secondary care.  

    Grey

    Not recommended as no formal application made for addition to the formulary. Contact relevant pharmacy team for further information.   

    Non Formulary

    Non-Formulary (category under review).  

    netFormulary